PE17.01 Baseline host determinants of robust human HIV vaccine responses ' a meta-analysis of 26 vaccine regimensE-posterInnate and trained immunity
PE17.02 Recombinant human (rh)ERAPs anti-HIV effect relies on activation of innate immunityE-posterInnate and trained immunity
PE18.01 Estimating the impact of PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir/emtricitabine among men who have sex with men in the United States: mathematical modelling for HPTN 083E-posterMathematical modelling: impact and effectiveness
PE18.02 Predicting PrEP efficacy in women with partial adherence to tenofovir disoproxil fumarate/emtricitabineE-posterMathematical modelling: impact and effectiveness
PE19.01 Population-level correlation between incidence of selected sexually transmitted infections and HIV-1 among women participating in HIV pre-exposure prophylaxis trials in AfricaE-posterMicrobiome & STI: impact on prevention
PE19.02 Immunomodulatory properties of cervicovaginal Lactobacillus isolates are associated with lactic acid production and bacterial proteome profilesE-posterMicrobiome & STI: impact on prevention
PE19.03 Lactic acid produced by an optimal vaginal microbiota promotes cervicovaginal epithelial barrier integrity: implications for HIV transmissionE-posterMicrobiome & STI: impact on prevention
PE19.04 Correlates of STI acquisition during the first years after sexual initiation: a longitudinal cohort study of sexually inexperienced adolescent girls and young women in KenyaE-posterMicrobiome & STI: impact on prevention
PE19.05 Cervicovaginal microbiota affects the human ectocervical epithelial barrier as determined by in situ image analysis and protein profilingE-posterMicrobiome & STI: impact on prevention
PE19.06 Female genital tract secretions obtained in the setting of bacterial vaginosis enhance HIV infectionE-posterMicrobiome & STI: impact on prevention
seek-warrow-warrow-eseek-e191 - 200 of 444 items